| Melinda Ann Henry, MA, CCC-A | |
|
1720 Ohiohealth Way Fl 2, Ashland, OH 44805-9253 | |
| (419) 756-5500 | |
| (419) 756-5502 |
| Full Name | Melinda Ann Henry |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 24 Years |
| Location | 1720 Ohiohealth Way Fl 2, Ashland, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457514077 | NPI | - | NPPES |
| 0016050 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | A01327 (Ohio) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ohiohealth Corporation | 6305758426 | 1900 |
News Archive
While Delta (B.1.617.2) has overtaken Alpha (B.1.1.7) as the dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant in the United States, Alpha remained a force to be reckoned with in New York City earlier this year. New research published on the preprint medRxiv* server details breakthrough infections in vaccinated and unvaccinated individuals living in New York City.
Merck, known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor.
A pair of targeted therapies shrank tumors in some patients with treatment-resistant Ewing's sarcoma or desmoplastic small-round-cell tumors, according to research led by investigators from The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2012.
Nurses will use extreme measures to save their patients and parents; but if they were dying, they prefer less aggressive ones for themselves, according to results from an international survey on nurses' end-of-life preferences.
› Verified 9 days ago
| Provider Name | Ohiohealth Corporation |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1578545273 PECOS PAC ID: 6305758426 Enrollment ID: O20031105000532 |
News Archive
While Delta (B.1.617.2) has overtaken Alpha (B.1.1.7) as the dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant in the United States, Alpha remained a force to be reckoned with in New York City earlier this year. New research published on the preprint medRxiv* server details breakthrough infections in vaccinated and unvaccinated individuals living in New York City.
Merck, known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor.
A pair of targeted therapies shrank tumors in some patients with treatment-resistant Ewing's sarcoma or desmoplastic small-round-cell tumors, according to research led by investigators from The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2012.
Nurses will use extreme measures to save their patients and parents; but if they were dying, they prefer less aggressive ones for themselves, according to results from an international survey on nurses' end-of-life preferences.
› Verified 9 days ago
| Provider Name | Wooster Ent Associates Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1427110527 PECOS PAC ID: 6204739311 Enrollment ID: O20040128000177 |
News Archive
While Delta (B.1.617.2) has overtaken Alpha (B.1.1.7) as the dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant in the United States, Alpha remained a force to be reckoned with in New York City earlier this year. New research published on the preprint medRxiv* server details breakthrough infections in vaccinated and unvaccinated individuals living in New York City.
Merck, known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor.
A pair of targeted therapies shrank tumors in some patients with treatment-resistant Ewing's sarcoma or desmoplastic small-round-cell tumors, according to research led by investigators from The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2012.
Nurses will use extreme measures to save their patients and parents; but if they were dying, they prefer less aggressive ones for themselves, according to results from an international survey on nurses' end-of-life preferences.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melinda Ann Henry, MA, CCC-A Po Box 7527, Dublin, OH 43017-0727 Ph: (419) 520-2495 | Melinda Ann Henry, MA, CCC-A 1720 Ohiohealth Way Fl 2, Ashland, OH 44805-9253 Ph: (419) 756-5500 |
News Archive
While Delta (B.1.617.2) has overtaken Alpha (B.1.1.7) as the dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant in the United States, Alpha remained a force to be reckoned with in New York City earlier this year. New research published on the preprint medRxiv* server details breakthrough infections in vaccinated and unvaccinated individuals living in New York City.
Merck, known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor.
A pair of targeted therapies shrank tumors in some patients with treatment-resistant Ewing's sarcoma or desmoplastic small-round-cell tumors, according to research led by investigators from The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2012.
Nurses will use extreme measures to save their patients and parents; but if they were dying, they prefer less aggressive ones for themselves, according to results from an international survey on nurses' end-of-life preferences.
› Verified 9 days ago
Dr. Alison B Chapin, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 2212 Mifflin Ave Ste 130, Ashland, OH 44805 Phone: 419-289-1937 | |
Alyssa Rech, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 1060 Claremont Ave, Ashland, OH 44805 Phone: 419-289-7626 |